(MedPage Today) — Among U.S. adults with diabetes and steatotic liver disease in the All of Us cohort, new use of a GLP-1 receptor agonist was linked with a 38% to 42% lower risk of hepatic events over nearly 3 years of median follow-up. (American…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
